Effects of intravenous dofetilide in patients with frequent premature ventricular contractions: A clinical trial

Abstract

SummaryBackground: Although suppression of premature ventricular contractions (PVCs) is not a predictor of mortality over the long term, the extent of PVC suppression is an important characteristic of any antiarrhythmic drug.Hypothesis: This study was undertaken to determine whether intravenous (IV) dofetilide has the ability to suppress PVCs in patients who have frequent occurrences.Methods: Subjects were men and women, aged 18 to 75

Infrequent Intraprocedural Premature Ventricular Complexes: Implications for Ablation Outcome

“…All patients had a 12‐lead 24‐hour Holter monitor prior to the ablation procedure. The Holter was repeated 3 months postablation and success was defined as a reduction of the initial PVC burden by ≥80% . Before ablation, variability of the PVC burden was assessed with 2 different Holter monitors 171 ± 229 days apart.…”

Dofetilide: a new drug to control cardiac arrhythmia

“…In small, dose-ranging studies intravenously administrated dofetilide were found to be effective in suppression of premature ventricular contractions in ∼ 50% of patients [42]. Inducible sustained VT in serial electrophysiological testing was also suppressed in 43 -46% of patients in two additional small-scale, dose-finding studies [43,44].…”